Exchange: NASDAQ·Updated 09:45 AM EDT

OPK News

News
all
press releases
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
Zacks
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
Zacks
More News
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
DOCS extends its 13-year partnership with U.S. News, strengthening its role in physician searches, appointment booking and hospital rankings.
Zacks
Natera Gains 118.1% in a Year: What's Driving the Rally?
NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
Zacks
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?
Zacks
Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35%
(RTTNews) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference Health, a subsidiary of OPKO Health Inc. (OPK...
Nasdaq News: Markets
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthPR NewswireBURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026Acquisition will expand access to clinical...
PR Newswire
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Zacks
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows.
Zacks
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?
BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outlook.
Zacks
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.
Zacks

Advertisement|Remove ads.